OZEMPIC Sales Forecast, and Market Size Analysis - 2034
상품코드:1855040
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
OZEMPIC의 주요 성장 촉진요인
1. 시장 점유율 확대 및 신규 환자 확보
오젬픽은 제 2형 당뇨병과 체중 관리 부문에서 큰 시장 점유율을 지속적으로 확보하고 있습니다.
의사의 신뢰도 향상과 환자들의 강력한 수요에 힘입어 신규 환자 수가 크게 증가하면서 처방액 증가를 촉진하고 있습니다.
노보 노디스크의 강력한 상업적 전략, 소비자 직접 판매 캠페인, 의료진에 대한 교육 노력은 채택을 더욱 가속화시키고 있습니다.
2. 주요 적응증 확대
제2형 당뇨병 : 오젬픽은 혈당 조절에 있어 주요 GLP-1 수용체 작용제 중 하나이며, 심혈관계에 대한 혜택이 그 가치 제안에 추가되었습니다.
비만/체중 관리 : 체중조절에 대한 적응증 외/내 적응증으로 사용되며, 좋은 임상결과에 힘입어 환자 기반이 확대되고 있습니다.
심혈관계 위험 감소 : 주요 심혈관계 질환을 감소시키는 효과가 입증되어 고위험군에서의 채택이 가속화되고 있습니다.
파이프라인 개발 : 비알코올성지방간염(NASH), 알츠하이머병, 심부전을 대상으로 한 임상시험이 진행 중으로 향후 적응증 확대가 기대됩니다.
3. 지리적 확장
OZEMPIC은 미국, 유럽, 일본에서 널리 사용되고 있으며, 신흥 시장으로 계속 확대되고 있습니다.
아시아태평양에서는 당뇨병 유병률 증가, 첨단 치료법 접근성 향상, 비만에 대한 인식 증가 등으로 인해 가장 빠른 보급이 예상됩니다.
Novo Nordisk는 급증하는 세계 수요에 대응하기 위해 현지 제조 역량을 강화하고 유통망을 강화하고 있습니다.
4. 신규 적응증 승인
제2형 당뇨병 환자의 심혈관계 위험 감소에 대한 적응증 확대가 규제 당국의 승인을 받아 치료 환경이 확대되었습니다.
비만 관련 적응증에 대한 승인 신청과 심혈관계 결과와 함께 그 지위는 더욱 강화될 것입니다.
5. 강력한 당뇨병 및 비만 수량 모멘텀
제 2형 당뇨병은 계속해서 성장의 핵심이며, 처방 건수는 지속적으로 두 자릿수 증가세를 보이고 있습니다.
비만 치료에 대한 수요가 빠르게 증가하고 있으며, OZEMPIC은 Wegovy와 병행하거나 Wegovy의 교량 역할을 하는 경우가 많아 GLP-1 분야에서 Novo Nordisk의 리더십이 강화되고 있습니다.
노보 노디스크의 2025 업데이트는 당뇨병과 체중 관리 부문에서 지속적인 처방 확대를 강조하고 있으며, 이는 설득력 있는 실제 임상 효능 데이터를 바탕으로 하고 있습니다.
6. 경쟁사와의 차별화와 시장 동향
오젬픽의 주 1회 주사라는 프로파일은 매일 투여하는 GLP-1 치료제 대비 편의성이 뛰어나 복약 순응도를 높입니다.
혈당 조절, 체중 감소, 심혈관 보호 등 심혈관계에 대한 효과가 입증되어 경쟁하는 많은 항당뇨병제와는 차별화되는 특징이 있습니다.
비만 치료, 맞춤형 의료, 심대사 위험 관리로의 전환과 같은 광범위한 시장 트렌드가 오젬픽의 입지를 강력하게 뒷받침하고 있습니다.
리얼월드에비던스(RWE)와 장기결과 데이터에 대한 신뢰가 높아지면서 보험사의 신뢰가 강화되고, 보험금 지급 범위가 확대되고 있습니다.
병용요법 및 경구용 GLP-1 제제(예 : Rybelsus)로의 전환은 노보 노디스크의 포트폴리오에서 오젬픽의 역할을 더욱 완벽하게 만들어주고 있습니다.
본 보고서는 OZEMPIC의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본) 시장을 조사 분석했으며, 매출 예측, 작용기전(MoA), 용법·용량, 연구개발(R&D)에 관한 정보를 전해드립니다.
목차
제1장 보고서 소개
제2장 OZEMPIC 개요 : 2형 당뇨병, 비만, 만성 신장병, 대사 관련 지방간염(MASH) 등의 승인된 적응증, 말초동맥질환, 알츠하이머병, 간경변, 1형 당뇨병 등의 잠재적 적응증
제품 상세
OZEMPIC 임상 개발
OZEMPIC 임상 연구
OZEMPIC 임상시험 정보
안전성과 유효성
기타 개발 활동
제품 프로파일
제3장 OZEMPIC 경쟁 구도(출시된 치료제)
제4장 경쟁 구도(후기 단계 신규 OZEMPIC 치료제)
제5장 OZEMPIC 시장 평가
승인된/잠재적 적응증에서 OZEMPIC 시장 전망
주요 7개 시장 분석
주요 7개 시장의 승인된/잠재적 적응증에 대한 OZEMPIC 시장 규모
각국의 시장 분석
미국의 승인된/잠재적 적응증에 대한 OZEMPIC 시장 규모
독일의 승인된/잠재적 적응증에 대한 OZEMPIC 시장 규모
영국의 승인된/잠재적 적응증에 대한 OZEMPIC 시장 규모
제6장 OZEMPIC SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 보고서 구입 옵션
KSM
영문 목차
영문목차
Key Factors Driving OZEMPIC Growth
1. Market Share Gains and New Patient Starts
OZEMPIC continues to capture substantial market share across the type 2 diabetes and weight management segments.
A significant rise in new patient starts, fueled by increasing physician confidence and strong patient demand, is driving prescription growth.
Novo Nordisk's robust commercial strategy, direct-to-consumer campaigns, and healthcare provider education initiatives are further accelerating adoption.
2. Expansion Across Key Indications
Type 2 Diabetes: OZEMPIC remains one of the leading GLP-1 receptor agonists for glycemic control, with cardiovascular benefits adding to its value proposition.
Obesity/Weight Management: Strong off-label and on-label use for weight management is expanding its patient base, supported by favorable real-world outcomes.
Cardiovascular Risk Reduction: Demonstrated efficacy in reducing major adverse cardiovascular events is boosting adoption in high-risk populations.
Pipeline Developments: Ongoing trials in non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and heart failure suggest potential future indications that could broaden its market reach.
3. Geographic Expansion
OZEMPIC is widely available in the US, Europe, and Japan, with expansion continuing into emerging markets.
The Asia-Pacific region is expected to see the fastest uptake, driven by rising diabetes prevalence, improving access to advanced therapies, and growing obesity awareness.
Novo Nordisk is enhancing local manufacturing capacity and strengthening distribution networks to meet surging global demand.
4. New Indication Approvals
Regulatory approvals for expanded use in cardiovascular risk reduction in patients with type 2 diabetes broaden its treatment landscape.
Ongoing regulatory submissions for obesity-related indications and cardiovascular outcomes will further strengthen positioning.
5. Strong Diabetes and Obesity Volume Momentum
Type 2 diabetes remains the core growth driver, with consistent double-digit prescription volume increases.
Obesity care demand is accelerating rapidly, with OZEMPIC often prescribed alongside or as a bridge to Wegovy, reinforcing Novo Nordisk's leadership in the GLP-1 space.
Novo Nordisk's 2025 updates highlight sustained prescription growth across both diabetes and weight management segments, supported by compelling real-world efficacy data.
6. Competitive Differentiation and Market Trends
Once-weekly injection profile of OZEMPIC offers superior convenience compared to daily GLP-1 therapies, enhancing adherence.
Proven cardiometabolic benefits (glycemic control, weight loss, cardiovascular protection) set it apart from many competing antidiabetic drugs.
Broader market trends such as the shift toward obesity care, personalized medicine, and cardiometabolic risk management strongly support OZEMPIC's positioning.
Growing reliance on Real-World Evidence (RWE) and long-term outcomes data is reinforcing payer confidence and expanding reimbursement coverage.
The increasing move toward combination therapies and oral GLP-1 formulations (e.g., Rybelsus) further complements OZEMPIC's role in Novo Nordisk's portfolio.
OZEMPIC Recent Developments
In September 2025, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, OZEMPIC (once-weekly injectable semaglutide) was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%. The data span nearly 60,000 US Medicare patients (aged >=66 years) living with type 2 diabetes, atherosclerotic cardiovascular disease (ASCVD) - a condition where fatty deposits build up in blood vessels, reducing blood flow and increasing the risk of heart attacks, strokes and related problems - and multiple health conditions. The results were presented at the European Association for the Study of Diabetes (EASD) 2025.
In August 2025, Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved OZEMPIC (semaglutide) for USD 499 per month, as part of the company's ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines. This offer is available through multiple platforms to eligible patients with a prescription for OZEMPIC and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay.
In June 2025, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an update of the OZEMPIC (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
"OZEMPIC Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of OZEMPIC for approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus in the 7MM. A detailed picture of OZEMPIC's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the OZEMPIC for approved and potential indications. The OZEMPIC market report provides insights about OZEMPIC's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OZEMPIC performance, future market assessments inclusive of the OZEMPIC market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OZEMPIC sales forecasts, along with factors driving its market.
OZEMPIC Drug Summary
OZEMPIC (semaglutide) injection 0.25 mg, 0.5 mg, 1.0 mg or 2.0 mg is a once-weekly GLP-1 RA indicated, along with diet and exercise, to improve blood sugar (glucose) in adults with type 2 diabetes and to reduce the risk of major CV events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease. OZEMPIC is the only GLP-1 RA indicated to reduce the risk of worsening kidney disease and risk of death from CV events in adults with type 2 diabetes and CKD. OZEMPIC is currently marketed in 72 countries, and 7 million people with type 2 diabetes are currently being treated with OZEMPIC worldwide. The report provides OZEMPIC's sales, growth barriers and drivers, post usage and approvals in multiple indications.
OZEMPIC is in the Phase III stage of clinical development for the treatment of patients with Alzheimer's disease (NCT04777396) and Peripheral Arterial Disease (NCT04560998); in Phase II stage for Liver Cirrhosis (NCT03987451); and in Phase I stage for type 1 diabetes mellitus (NCT07087795).
Scope of the OZEMPIC Market Report
The report provides insights into:
A comprehensive product overview including the OZEMPIC MoA, description, dosage and administration, research and development activities in approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus.
Elaborated details on OZEMPIC regulatory milestones and other development activities have been provided in OZEMPIC market report.
The report also highlights OZEMPIC's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The OZEMPIC market report also covers the patents information, generic entry and impact on cost cut.
The OZEMPIC market report contains current and forecasted OZEMPIC sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The OZEMPIC market report also features the SWOT analysis with analyst views for OZEMPIC in approved and potential indications.
Methodology:
The OZEMPIC market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OZEMPIC Analytical Perspective by DelveInsight
In-depth OZEMPIC Market Assessment
This OZEMPIC sales market forecast report provides a detailed market assessment of OZEMPIC for approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OZEMPIC sales data uptil 2034.
OZEMPIC Clinical Assessment
The OZEMPIC market report provides the clinical trials information of OZEMPIC for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
OZEMPIC Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
OZEMPIC Market Potential & Revenue Forecast
Projected market size for the OZEMPIC and its key indications
Commercial partnerships, licensing deals, and M&A activity
OZEMPIC Clinical Differentiation
OZEMPIC Efficacy & safety advantages over existing drugs
OZEMPIC Unique selling points
OZEMPIC Market Report Highlights
In the coming years, the OZEMPIC market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The OZEMPIC companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OZEMPIC's dominance.
Other emerging products for type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus are expected to give tough market competition to OZEMPIC and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OZEMPIC in approved and potential indications.
Analyse OZEMPIC cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted OZEMPIC sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OZEMPIC in approved and potential indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of OZEMPIC? How strong is OZEMPIC's clinical and commercial performance?
What is OZEMPIC's clinical trial status in each individual indications such as type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OZEMPIC Manufacturers?
What are the key designations that have been granted to OZEMPIC for approved and potential indications? How are they going to impact OZEMPIC's penetration in various geographies?
What is the current and forecasted OZEMPIC market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of OZEMPIC in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to OZEMPIC for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is OZEMPIC? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. OZEMPIC Overview in approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus
